Cellular and molecular aspects of drugs of the future: oxaliplatin

[1]  M. Marinus,et al.  MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA* , 2002, The Journal of Biological Chemistry.

[2]  A. Norman,et al.  An oxaliplatin‐based chemotherapy in patients with relapsed or refractory intermediate and high‐grade non‐Hodgkin's lymphoma , 2001, British journal of haematology.

[3]  S. Guichard,et al.  Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo , 2001, Anti-cancer drugs.

[4]  B. Baguley,et al.  Nucleolar damage correlates with neurotoxicity induced by different platinum drugs , 2001, British Journal of Cancer.

[5]  M. Piccart,et al.  Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Hector,et al.  In vitro studies on the mechanisms of oxaliplatin resistance , 2001, Cancer Chemotherapy and Pharmacology.

[7]  E. Gamelin,et al.  [Pharmacokinetic properties of platinium derivatives]. , 2001, Bulletin du cancer.

[8]  E. Gamelin,et al.  A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. , 2001, Journal of neurophysiology.

[9]  S. Brienza,et al.  Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  E. Raymond,et al.  Oxaliplatin-induced damage of cellular DNA. , 2000, Molecular pharmacology.

[11]  S. Johnson,et al.  Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. , 2000, Biochemical pharmacology.

[12]  Anastassis Perrakis,et al.  The crystal structure of DNA mismatch repair protein MutS binding to a G·T mismatch , 2000, Nature.

[13]  Wei Yang,et al.  Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA , 2000, Nature.

[14]  J. Yu,et al.  Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues. , 2000, Oncology reports.

[15]  P. Jordan,et al.  Molecular mechanisms involved in cisplatin cytotoxicity , 2000, Cellular and Molecular Life Sciences CMLS.

[16]  F. Hanaoka,et al.  Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. , 2000, Biochemistry.

[17]  R. Fishel,et al.  The Role of Mismatched Nucleotides in Activating the hMSH2-hMSH6 Molecular Switch* , 2000, The Journal of Biological Chemistry.

[18]  R. Liskay,et al.  Mammalian DNA mismatch repair. , 1999, Annual review of genetics.

[19]  X. Lin,et al.  The role of DNA mismatch repair in cisplatin mutagenicity. , 1999, Journal of inorganic biochemistry.

[20]  Eric D. Scheeff,et al.  Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. , 1999, Molecular pharmacology.

[21]  S. Chaney,et al.  Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. , 1999, Cancer research.

[22]  Jijie Gu,et al.  p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage , 1999, Nature.

[23]  Antonio Costanzo,et al.  The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage , 1999, Nature.

[24]  Reuven Agami,et al.  Interaction of c-Abl and p73α and their collaboration to induce apoptosis , 1999, Nature.

[25]  S. Wyrick,et al.  High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[26]  R. Wood,et al.  Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours , 1999, Current Biology.

[27]  J. Wang,et al.  Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells , 1999, British Journal of Cancer.

[28]  H. Takano,et al.  Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. , 1999, Cancer research.

[29]  C. Napier,et al.  Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. , 1998, Molecular pharmacology.

[30]  E. Reed.  Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. , 1998, Cancer treatment reviews.

[31]  T. Kunkel,et al.  The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. , 1998, Cancer research.

[32]  E. Cvitkovic.  Ongoing and unsaid on oxaliplatin: the hope. , 1998, British Journal of Cancer.

[33]  J. Armand,et al.  Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC) , 1998 .

[34]  S. Lippard,et al.  Solution Structure of a DNA Duplex Containing a Nitroxide Spin-Labeled Platinum d(GpG) Intrastrand Cross-Link Refined with NMR-Derived Long-Range Electron−Proton Distance Restraints , 1998 .

[35]  E. Raymond,et al.  Oxaliplatin: mechanism of action and antineoplastic activity. , 1998, Seminars in oncology.

[36]  E. Raymond,et al.  Activity of oxaliplatin against human tumor colony-forming units. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  S. Lippard,et al.  Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. , 1998, Biochemistry.

[38]  R. Fishel,et al.  The Human Mismatch Recognition Complex hMSH2-hMSH6 Functions as a Novel Molecular Switch , 1997, Cell.

[39]  P. Modrich.  Strand-specific Mismatch Repair in Mammalian Cells* , 1997, The Journal of Biological Chemistry.

[40]  J. L. Fink,et al.  Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  S. Aebi,et al.  Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. , 1997, Cancer research.

[42]  J. Hoffmann,et al.  HMG1 protein inhibits the translesion synthesis of the major DNA cisplatin adduct by cell extracts. , 1997, Journal of molecular biology.

[43]  A. V. D. Van Der Zee,et al.  hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents , 1997, Oncogene.

[44]  C. Macleod,et al.  In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. , 1997, Cancer research.

[45]  P. Karran,et al.  Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. , 1997, Nucleic acids research.

[46]  K. Paull,et al.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.

[47]  R. Rietbroek,et al.  In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. , 1996, Carcinogenesis.

[48]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[49]  H. Naegeli,et al.  Recognition of DNA Adducts by Human Nucleotide Excision Repair , 1996, The Journal of Biological Chemistry.

[50]  S. Chaney,et al.  DNA repair: enzymatic mechanisms and relevance to drug response. , 1996, Journal of the National Cancer Institute.

[51]  E. Raymond,et al.  Synergy between the non‐classical thymidylate synthase inhibitor AG337 (ThymitaqR) and cisplatin in human colon and ovarian cancer cells , 1996, Anti-cancer drugs.

[52]  J. Jiricny,et al.  hMutSβ, a heterodimer of hMSH2 and hMSH3, binds to insertion/deletion loops in DNA , 1996, Current Biology.

[53]  P. Modrich,et al.  Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line* , 1996, The Journal of Biological Chemistry.

[54]  R. Perez,et al.  Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. , 1996, Cancer letters.

[55]  J. Essigmann,et al.  The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. , 1996, Chemistry & biology.

[56]  C. Boland,et al.  Loss of DNA mismatch repair in acquired resistance to cisplatin. , 1996, Cancer research.

[57]  G. A. van der Marel,et al.  Structural effect of intra-strand cisplatin-crosslink on palindromic DNA sequences. , 1996, Journal of biomolecular structure & dynamics.

[58]  T. Kunkel,et al.  DNA-replication fidelity, mismatch repair and genome instability in cancer cells. , 1996, European journal of biochemistry.

[59]  K. Yarema,et al.  Analysis of Incision Sites Produced by Human Cell Extracts and Purified Proteins during Nucleotide Excision Repair of a 1,3-Intrastrand d(GpTpG)-Cisplatin Adduct (*) , 1996, The Journal of Biological Chemistry.

[60]  R. Brown,et al.  Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. , 1996, Cancer research.

[61]  R. Perez,et al.  Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. , 1995, Cancer letters.

[62]  S. Lippard,et al.  Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin , 1995, Nature.

[63]  M. Hawn,et al.  Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. , 1995, Cancer research.

[64]  R. Weichselbaum,et al.  Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents , 1995, Nature.

[65]  J. Jiricny,et al.  GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. , 1995, Science.

[66]  P. Modrich,et al.  Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. , 1995, Science.

[67]  S. Chaney.  The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review). , 1995, International journal of oncology.

[68]  D. Picard,et al.  Cell cycle arrest by tyrosine kinase Abl involves altered early mitogenic response. , 1995, Oncogene.

[69]  S. Lippard,et al.  HMG domain proteins induce sharp bends in cisplatin-modified DNA. , 1994, Biochemistry.

[70]  G. Aquilina,et al.  A mismatch recognition defect in colon carcinoma confers DNA microsatellite instability and a mutator phenotype. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[71]  L. Kèlland,et al.  New Platinum Agents , 1994 .

[72]  W. Kaufmann,et al.  Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. , 1994, Cancer research.

[73]  C. Sawyers,et al.  The nuclear tyrosine kinase c-abl negatively regulates cell growth , 1994, Cell.

[74]  L. Kèlland,et al.  New platinum antitumor complexes. , 1993, Critical reviews in oncology/hematology.

[75]  P. J. Welch,et al.  A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle , 1993, Cell.

[76]  S. Lippard,et al.  Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. , 1993, Science.

[77]  W. Thilly,et al.  An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[78]  S. Howell,et al.  Cellular accumulation of the anticancer agent cisplatin: a review. , 1993, British Journal of Cancer.

[79]  G. Aquilina,et al.  Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage , 1993, Nature.

[80]  S. Chaney,et al.  Role of carrier ligand in platinum resistance of human carcinoma cell lines. , 1993, Cancer research.

[81]  M. Christian.  The current status of new platinum analogs. , 1992, Seminars in oncology.

[82]  S. Lippard,et al.  An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[83]  V. Brabec,et al.  Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. , 1992, Nucleic acids research.

[84]  W. Kaufmann,et al.  Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. , 1991, Carcinogenesis.

[85]  P. Andrews,et al.  Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. , 1991, Cancer research.

[86]  S. Lippard,et al.  Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. , 1990, Biochemistry.

[87]  F. Lévi,et al.  Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. , 1990, Journal of the National Cancer Institute.

[88]  D. K. Treiber,et al.  Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. , 1990, Biochemistry.

[89]  S. Chaney,et al.  Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. , 1990, Biochemistry.

[90]  R. Wood,et al.  Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum(II). , 1989, Nucleic acids research.

[91]  E. Pettersen,et al.  Modifying effect of cinnamaldehyde and cinnamaldehyde derivatives on cell inactivation and cellular uptake of cis-diamminedichloroplatinum(II) in human NHIK 3025 cells. , 1989, Cancer research.

[92]  S. Wyrick,et al.  Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. , 1988, Cancer research.

[93]  R. Hromas,et al.  Decreased cisplatin uptake by resistant L1210 leukemia cells. , 1987, Cancer letters.

[94]  C. Coltman,et al.  Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. , 1987, Cancer treatment reports.

[95]  K. Inagaki,et al.  Steric effect in binding of antitumor active platinum (II) complex to nucleic acid base. , 1985, Chemical & pharmaceutical bulletin.

[96]  M. Kris,et al.  Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  S. Legha,et al.  High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  D. Barnes,et al.  A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells. , 1985, Cancer research.

[99]  P. Daley-Yates,et al.  The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity. , 1985, Biochemical pharmacology.

[100]  S. Waxman,et al.  Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. , 1983, Cancer research.

[101]  Greco Fa,et al.  Cisplatin-induced anemia. , 1980 .

[102]  J. Wiencke,et al.  Mutagenic activity of anticancer agent cis-dichlorodiammine platinum-II. , 1979, Mutation research.

[103]  L. M. Atkins,et al.  Synergistic action of high‐dose hydroxyurea when used with cyglophosphamide and certain new organoplatinum complexes in treatment of advanced L1210 leukemia , 1978, Cancer.

[104]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[105]  A. Lasorella,et al.  Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors , 2004, Cancer Chemotherapy and Pharmacology.

[106]  M. Espié,et al.  Phase I study of oxaliplatin in patients with advanced cancer , 2004, Cancer Chemotherapy and Pharmacology.

[107]  K. Valerie,et al.  A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin. , 2001, Cancer research.

[108]  R Mastrangelo,et al.  Antitumour activity of oxaliplatin in neuroblastoma cell lines. , 1999, European journal of cancer.

[109]  J. T. Reardon,et al.  Molecular Mechanism of Nucleotide Excision Repair in Mammalian Cells , 1999 .

[110]  S. Wyrick,et al.  Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. , 1998, Oncology research.

[111]  R. Perez,et al.  Induction of gamma-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line. , 1996, Oncology research.

[112]  A. Sancar.  DNA excision repair. , 1996, Annual review of biochemistry.

[113]  R. Wood.  DNA repair in eukaryotes. , 1996, Annual review of biochemistry.

[114]  S. Howell,et al.  Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. , 1990, Cancer communications.

[115]  J. Engel,et al.  Tumor Inhibiting Properties of Stereoisomeric [1,2‐Bis (3‐hydroxyphenyl)ethylenediamine]dichloroplatinum(II)‐Complexes, Part II: Biological Properties , 1989, Archiv der Pharmazie.

[116]  J. Misset,et al.  Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[117]  W. Kaufmann.  Pathways of human cell post-replication repair. , 1989, Carcinogenesis.

[118]  T. Tashiro,et al.  Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[119]  A. Eastman,et al.  Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. , 1989, Chemico-biological interactions.

[120]  J. Misset,et al.  A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). , 1986, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[121]  M. Hrubiško,et al.  Comparison of the effectivity of two diaminocyclohexane Pt-complexes. , 1985, Neoplasma.